For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue-License | - | -26,706* | - | - |
| Restructuring | - | 0* | 0 | 0 |
| Total revenue | 127,199 | - | 164,859 | 114,449 |
| In-process research and development | - | 0* | 0 | 0 |
| Product | - | 3,583* | - | - |
| License | - | -1,028* | - | - |
| Total revenue-Product | - | 156,394* | - | - |
| Cost of goods sold | 1,950 | 2,554 | 1,585 | 1,521 |
| Research and development | 57,094 | 57,870 | 51,890 | 49,362 |
| Selling, general and administrative | 80,254 | 101,695 | 86,453 | 76,216 |
| Royalty expense | 24,816 | - | - | - |
| Total operating expenses | 164,114 | 162,119 | 139,928 | 127,099 |
| Operating loss | -36,915 | -32,431 | 24,931 | -12,650 |
| Interest income | 2,584 | 2,592 | 3,047 | 3,287 |
| Interest expense | 2,300 | 2,294 | 2,751 | 2,846 |
| Other (expense) income, net | -91 | 11,068 | 487 | -526 |
| Total other income, net | 193 | 11,366 | 783 | -85 |
| Loss from continuing operations before income tax | -36,722 | -21,065 | 25,714 | -12,735 |
| Income tax benefit (provision) on continuing operations | -120 | 921 | 8 | 20 |
| Loss from continuing operations, net of tax | -36,602 | -21,986 | 25,706 | -12,755 |
| Loss from discontinued operations, net of tax | -500 | 24,715 | 0 | 0 |
| Unrealized gain (loss) on defined benefit pension plan | - | -219 | - | - |
| Net gain | -37,102 | 2,729 | 25,706 | -12,755 |
| Foreign currency translation gain (loss) | 447 | -243 | -284 | 268 |
| Unrealized loss on marketable debt securities | -320 | -111 | 42 | -237 |
| Comprehensive gain | -36,975 | 2,594 | 25,464 | -12,724 |
| Basic EPS | -0.4 | 0.029 | 0.29 | -0.14 |
| Diluted EPS | -0.4 | 0.034 | 0.28 | -0.14 |
| Basic Average Shares | 91,868,862 | 90,315,235 | 89,230,420 | 88,945,624 |
| Diluted Average Shares | 91,868,862 | 76,927,095 | 102,618,560 | 88,945,624 |
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)